How CloSYS Works
CloSYS contains Cloralstan®, a patented ingredient whose main ingredient is stabilized chlorine dioxide. When CloSYS is exposed to the acidic areas where plaque has formed, the chlorine dioxide is released. Once released, the chlorine dioxide kills dental plaque-causing bacteria and volatile sulfur compounds that damage soft tissue.
One of the ways Cloralstan® works is through oxidation of the sulfide bonds in VSCs. The chlorine dioxide in CloSYS reacts with the molecules that cause bad breath, and destroys them. Unlike other products, CloSYS does not cover up the unpleasant smells; it eliminates them.
A Patented, Stabilized Chlorine Dioxide Ingredient
Cloralstan® is a highly effective oxidant in the form of a stable dissolved gas. Cloralstan® has long been recognized as a very effective antimicrobial for its disinfection and sterilizing properties, and has been approved by the Environmental Protection Agency for industrial use as an eco-friendly food disinfectant and drinking water treatment.
Cloralstan® attacks microorganisms, destroys major pathogens associated with gum disease and inhibits their re-growth. No other antimicrobial has proved to control biofilm and respond to tooth decay and gum disease better than chlorine dioxide. The patented CIO2 ingredient in CloSYS is found in all our oral products, and when they are used together, can provide your patients with maximum oral health.
Chlorine Dioxide Safety
Rowpar Pharmaceuticals, Inc. produces the patented, buffered chlorine dioxide ingredient known as Cloralstan®. The active ingredient in CloSYS is a stabilized molecular form of chlorine dioxide. Chlorine dioxide is one of the safest ingredients used in the food industry today. This active ingredient in CloSYS is an effective and safe antibacterial agent that requires no mixing to activate.
Extensive literature related to the pharmacology, toxicology, and safety of chlorine dioxide and stabilized chlorine dioxide is readily available. The Environmental Protection Agency and the Agency for Toxic Substances and Disease Registry have both developed toxicological profiles for chlorine dioxide.
No adverse events linked to normal product use have been reported during Rowpar Pharmaceuticals' sponsored clinical studies or since the product's release to the consumer market in 1991.
Toxicological Review of Chlorine Dioxide and Chlorite, US Environmental Projection Agency. September 2000.
Toxicological Profile for Chlorine Dioxide and Chlorite. US Department of Health and Human Services, Agency for Toxic Substances and Disease
Registry. September 2004.
Wirthlin MR, Ahn BJ, et al. Effects of stabilized chlorine dioxide and chlorhexidine mouth rinses in vitro on cells involved in periodontal healing. Journal of West Society Periodontology/Periodontal Abstracts 2006; 54(3), 67-71.
Lynch E, Sheerin A, Claxson AW, et al. Multicomponent Spectroscopic Investigations of Salivary Antioxidant Consumption by an Oral Rinse Preparation Containing the Stable Free Radical Species Chlorine Dioxide. Free Radic Res. 1997; 26: 209-34.
CloSYS vs. Chlorhexidine
M. Robert Wirthlin, DDS, Brand J AHN, DDS, Belma Enriquez, BS, and M. Zamirul Hussain, PhD. Effects of stabilized chlorine dioxide
and chlorhexidine mouthrinses in in vitro cells involved in periodontal healing. Periodontal Abstracts, The Journal of the Western Society of
Periodontology, vol. 54, no. 3, 2006.
David Drake, MS, PhD. Alissa L. Villhauer, BS, Dows Institute for Dental Research, College of Dentistry, University of Iowa An In Vitro Comparative Study Determining Bactericidal Activity of Stabilized Chlorine Dioxide and Other Oral Rinses Journal Clin Dent 2011;22:1-5
A New Standard
Recent testing shows that Rowpar Pharmaceuticals' CloSYS oral rinse compares to chlorhexidine (CHX) in many key aspects of post- procedure oral hygiene.
CloSYS was shown to have robust performance comparable to or better than CHX in killing oral bacteria. Unlike CHX, CloSYS does not interfere with fibroblasts, which are associated with the healing process. This distinction, reported by Dr. Robert Wirthlin, DDS, supports CloSYS's benefit in facilitating the healing process. Patients demonstrate noticeably improved oral health within a few weeks of making the rinse part of their daily routine.
The study conducted by David Drake, M.S., Ph.D., Professor of Microbiology and Director of Research in the Department of Endodontics at the University of Iowa, compared bactericidal activity of the CloSYS rinse to that of CHX (Peridex®). Each oral rinse was tested against a select group of bacteria known to be associated with periodontal disease and dental caries. In carefully standardized conditions, the rinses were introduced to the individual bacterial strains and the effectiveness in combating these periodontal pathogens was measured.
The kill rate for CloSYS surpassed that of CHX in the first minute for Actinomyces naeslundii (involved in periodontal disease and endodontic infections) and Peptostreptococcus micros (found in periodontal disease). The kill rate for Streptococcus mutans (causes caries) and Actinomyces viscosus (involved with oral infections) were higher for CHX in a first minute sample, but by five minutes, CloSYS and CHX samples proved identical at 100% kill rates. With Porphyromonas gingivalis (culpable in the progression of chronic periodontitis), Actinobacillus actinomycetemcomitans (causes localized aggressive periodontitis), Actinomyces odontolyticus (responsible for deep dental caries and chronic periodontitis) and Prevotella nigrescens (found in endodontic infections), both CloSYS and CHX achieved a 100% kill rate in the first minute.
CloSYS was also observed to exceed bactericidal properties against staphylococcus aureus, which is not necessarily an oral pathogen, but is the causative agent of staph infections. CloSYS exhibited 100% kill rate within the first minute of exposure.
With its strong performance against the oral bacteria that cause infections of the periodontium and endodontium, as well as dental caries and staph infections, and its favorable behavior toward healing cells (fibroblasts), CloSYS addresses a spectrum of clinical oral hygiene concerns. Finally, its agreeable taste and non-tooth-staining characteristics-especially coupled with its lower cost and over-the-counter convenience compared to its prescription counterpart-encourage patients to be fully compliant. As a non-prescription oral rinse, CloSYS not only meets and may surpass CHX in post-procedure applications, it also can be recommended for twice-daily regular oral care as a maintenance and preventative measure. CloSYS is now a premium standard for daily oral care.